🧬 Aging Wiki

disabled-macroautophagy

Properties1
aliasesautophagy decline, autophagy failure with aging, macroautophagy impairment

12 min read

Disabled macroautophagy

Age-associated decline in macroautophagy — the cellular bulk-degradation pathway by which damaged organelles, protein aggregates, and long-lived proteins are sequestered into double-membraned autophagosomes and delivered to the lysosome for degradation. Recognized as a separate Primary hallmark in the 2023 expansion of the hallmarks framework (López-Otín et al. 2023), having previously been subsumed under loss-of-proteostasis in the 2013 edition. The elevation of this hallmark to standalone status reflects a convergence of genetic, pharmacological, and epidemiological evidence establishing macroautophagy decline as a central, upstream driver of age-related cellular dysfunction across virtually all tissues and organisms studied. This hallmark is the wiki’s best-evidenced cluster, with 26 verified atomic pages seeded in Round 6 (2026-05-04) and verified by the wiki-verifier agent (2026-05-04).

Why macroautophagy was split from loss-of-proteostasis

The 2013 hallmarks treated autophagy as one arm of proteostasis, alongside the ubiquitin-proteasome-system and molecular chaperones. The 2023 revision elevated macroautophagy to its own hallmark on these grounds:

  1. Distinct molecular identity. Macroautophagy has dedicated, specific machinery — the ULK1 initiation complex, VPS34/Beclin-1 nucleation complex, two independent ATG conjugation cascades, and LC3 lipidation — that is mechanistically separate from the ubiquitin-proteasome system and from chaperone-mediated-autophagy (CMA).
  2. Organelle-level scope. Macroautophagy is the primary mechanism for clearing damaged organelles (via selective variants), which the proteasome and CMA cannot handle. Impaired mitophagy, for instance, is not interchangeable with impaired proteasomal function.
  3. Cross-hallmark pleiotropy. Macroautophagy decline contributes mechanistically to at least five other hallmarks: mitochondrial-dysfunction (via failing mitophagy), loss-of-proteostasis (aggregate accumulation), cellular-senescence (autophagy clears senescence-relevant components), stem-cell-exhaustion (HSC autophagy required for self-renewal), and chronic-inflammation (autophagy limits SASP). Treating it as a sub-aspect of proteostasis understated its reach.
  4. Therapeutic tractability. Multiple lifespan-extending interventions work partly or primarily through autophagy induction — rapamycin, spermidine, caloric-restriction — making it a first-class intervention target.

Core machinery (all verified atomic pages)

Autophagosome formation proceeds through five stages, each driven by a distinct protein set. All machinery pages below are verified.

StageComplex / ProteinsAtomic page
InitiationULK1 + ATG13 + FIP200 + ATG101 kinase complexulk1 (verified), atg13 (verified), atg101 (verified)
NucleationVPS34 + Beclin-1 + VPS15 + ATG14L → PI3P at phagophorebeclin-1 (verified)
Elongation — E3-likeATG12–ATG5–ATG16L1 conjugation systematg5 (verified), atg7 (verified), atg12 (verified)
Elongation — LC3LC3–PE lipidation via ATG7→ATG3lc3 (verified)
Flux readoutp62/SQSTM1 (cargo receptor + inverse flux reporter)p62 (verified)
Master transcriptionTFEB → CLEAR network (lysosomal biogenesis + autophagy genes)tfeb (verified)

Key regulatory inputs at initiation: mTORC1 phosphorylates and inhibits ULK1 (Ser757 in mouse; Ser758 in human) and ATG13 (Ser258); ampk phosphorylates and activates ULK1 (Ser317, Ser556 — human numbering per UniProt O75385). AMPK also suppresses mTORC1 via Raptor phosphorylation (Ser792), creating a mutually antagonistic switch — see ampk (verified) and mtor (verified) for mechanistic detail.

TFEB activity declines with age: under nutrient-replete conditions, mTORC1 phosphorylates TFEB at Ser142 and Ser211, retaining it in the cytoplasm. In aged tissues, chronic mTOR over-activation suppresses TFEB nuclear localization, reducing lysosomal biogenesis and autophagy gene expression — see tfeb (verified) for full detail. needs-human-replication — most TFEB aging-decline evidence is from rodent and C. elegans models.

Selective autophagy variants (all verified, Round 6)

Macroautophagy can be targeted to specific cargo via dedicated receptor proteins:

VariantCargoKey receptor proteinsAtomic page
mitophagyDamaged / depolarized mitochondriaPINK1 → Parkin → NDP52/OPTN/p62; BNIP3/NIX; FUNDC1 (hypoxia); BCL2L13mitophagy (verified)
lipophagyLipid dropletsATGL-related; LC3 interactionlipophagy (verified)
chaperone-mediated-autophagyKFERQ-motif soluble proteinsHSPA8 + LAMP-2A (lysosomal receptor)chaperone-mediated-autophagy (verified)
xenophagyIntracellular pathogensNDP52, OPTN, p62xenophagy (verified)

Selective autophagy variants have their own receptor proteins, each with LIR (LC3-Interacting Region) motifs that dock directly onto LC3 on the inner autophagosome membrane. The principal mitophagy receptors are ndp52 (primary, per Lazarou 2015 — see ndp52 verified) and optn (TBK1-dependent, Ser177 phosphorylation — see optn verified), with bnip3 and nix providing a Parkin-independent, receptor-mediated pathway relevant to hypoxic and developmental mitophagy — see bnip3 (verified) and nix (verified). fundc1 is the primary hypoxia-induced mitophagy receptor — see fundc1 (verified). bcl2l13 (the mammalian Atg32 ortholog) mediates Parkin-independent mitophagy downstream of AMPKα2 phosphorylation (Ser272) with cardioprotective relevance — see bcl2l13 (verified).

Genetic proof: autophagy is required for aging and longevity

These genetic experiments provide the most direct evidence linking macroautophagy to aging:

Loss-of-function — autophagy deficiency accelerates aging-like phenotypes:

  • Conditional neural Atg5 KO (Nestin-Cre) → progressive motor deficits + ubiquitin-positive inclusion bodies + neurodegeneration, recapitulating human neurodegenerative disease — see atg5 (verified) 1.
  • Conditional neural Atg7 KO (Nestin-Cre) → identical neurodegeneration phenotype, confirming ATG5 and ATG7 are non-redundant — see atg7 (verified) 2.
  • Beclin-1 haploinsufficiency (Becn1+/−) → reduced autophagy, increased tumor incidence in mice 3. needs-human-replication
DimensionStatus
Pathway conserved in humans?yes
Phenotype conserved in humans?partial (neurodegeneration yes; ATG5/ATG7 KO — human germline lethal)
Replicated in humans?no (genetic KO not feasible; Parkinson-disease PINK1/PARK2 mutations are partial proxy)

Gain-of-function — autophagy restoration extends lifespan:

  • ATG5 overexpression (systemic transgenic, Pyo 2013): ~17.2% lifespan extension in mice (χ²=17.32, p<0.001, n=65 WT + 70 Atg5 Tg) — see atg5 (verified) 4. needs-human-replication
  • Beclin-1 F121A knock-in (Fernández 2018): A point mutation disrupting the BCL-2/Beclin-1 interaction to constitutively de-repress autophagy extends median lifespan ~12% in male and female mice — see beclin-1 (verified) 5. needs-human-replication
DimensionStatus
Pathway conserved in humans?yes
Phenotype conserved in humans?unknown (no equivalent human genetic data)
Replicated in humans?no

Epistasis — autophagy is required for other longevity pathways:

Autophagy gene knockouts (bec-1, atg-7, atg-18 in C. elegans; Atg5-RNAi in Drosophila) abolish the lifespan extension conferred by caloric restriction, mTOR inhibition, IIS reduction, and sirtuin activation in worms and flies — see autophagy (verified) for the epistasis evidence aggregated from Hansen 2018 6. This makes autophagy a downstream convergence point for multiple longevity pathways, not merely one of several proteostatic arms. The hyperfunction-theory (verified) frames this as mTORC1 hyperactivity driving both anabolic overload and autophagy suppression simultaneously.

Age-associated autophagy decline: mechanisms

Autophagic flux declines progressively with age across tissues in multiple organisms. Mechanistic contributors (aggregated from autophagy verified + tfeb verified + mtor verified):

  1. Reduced ATG protein expression. Transcript and protein levels of ATG5, ATG7, BECN1, and LC3 decline in aged tissues across multiple species. Evidence is predominantly in rodent models; human data from peripheral blood cells and post-mortem brain tissue. needs-human-replication
  2. Lysosomal dysfunction. Accumulation of lipofuscin (oxidized, cross-linked protein-lipid aggregates) reduces lysosomal hydrolase activity and inhibits autophagosome–lysosome fusion. no-mechanism — the precise molecular mechanism of lipofuscin-induced lysosomal inhibition remains unclear.
  3. Chronic mTOR over-activation. Consistent with the hyperfunction-theory (verified), aged tissues maintain elevated mTORC1 activity even during nutritional stress, constitutively suppressing ULK1 and TFEB — see mtor (verified).
  4. TFEB nuclear exclusion. Age-associated TFEB hypo-activity reduces CLEAR network transcription, diminishing lysosomal biogenesis and autophagy gene expression — see tfeb (verified).
  5. p62/SQSTM1 accumulation. p62 accumulates in aged tissues as a marker of impaired autophagic flux and contributes to ubiquitin-positive inclusion body formation — see p62 (verified).
  6. Autophagosome–lysosome fusion failure. Impaired SNARE machinery and membrane lipid changes in aged lysosomes reduce fusion efficiency, producing a “traffic jam” of autophagosomes that cannot complete degradation. unsourced — this claim needs primary citations; mechanism is inferred from indirect evidence.

Cross-hallmark contributions

Macroautophagy decline is unusual among hallmarks in that it mechanistically contributes to multiple other hallmarks:

Downstream hallmarkAutophagy link
mitochondrial-dysfunctionFailing mitophagy allows damaged, ROS-generating mitochondria to accumulate — see mitophagy (verified)
loss-of-proteostasisBulk autophagy and aggrephagy are required to clear protein aggregates that overwhelm the proteasome
cellular-senescenceAutophagy degrades p21 and components of the SASP machinery; impaired autophagy stabilizes senescent phenotype — unsourced — needs dedicated primary citations
stem-cell-exhaustionHSC self-renewal requires autophagy for mitochondrial quality control; quiescent HSCs with impaired autophagy display metabolic stress and differentiation bias — needs-human-replication
chronic-inflammationAutophagy limits SASP secretion and clears DAMP-generating debris; impairment amplifies nf-kb-driven inflammation
deregulated-nutrient-sensingmTORC1 over-activation both causes nutrient-sensing deregulation and suppresses autophagy; the two hallmarks are tightly entangled at the mTORC1 hub

Deregulated nutrient-sensing entanglement

The mTORC1 axis forms the dominant mechanistic bridge between the deregulated-nutrient-sensing hallmark and this one:

  • mTORC1 active (nutrient excess / IIS over-signaling) → ULK1 inhibited → autophagy suppressed
  • mTORC1 active → TFEB Ser211 phosphorylated → cytoplasmic retention → CLEAR network silenced
  • AMPK active (energy stress) → ULK1 activated + mTORC1 suppressed → autophagy induced

This means rapamycin and caloric restriction act on both hallmarks simultaneously — see mtor (verified) for the mTOR mechanistic detail and ampk (verified) for the AMPK/ULK1 activation mechanism.

Therapeutic landscape

InterventionMechanism of autophagy inductionLifespan / healthspan evidenceAtomic page
rapamycinmTORC1 inhibition → ULK1 disinhibitionNIA ITP-validated mouse lifespan extension (multiple labs, both sexes)rapamycin (verified)
spermidineEP300 acetyltransferase inhibition → autophagy gene de-repressionMouse lifespan extension (Eisenberg 2016); observational human mortality association (Kiechl 2018 n=829, HR=0.74)spermidine (verified)
caloric-restrictionmTOR ↓ + AMPK ↑ → autophagy-inducing signalAutophagy required for CR longevity benefit (genetic epistasis in worms/flies)caloric-restriction (verified)
urolithin-aMitophagy inducer (postbiotic); ATLAS RCT (Singh 2022, n=88) — primary endpoint (peak power) NS vs placebo; aerobic endurance dose-dependent at 1000 mgPhase 2 RCT human data (limited)urolithin-a (verified)
ExerciseAcute AMPK activation + LC3 lipidation in skeletal muscle; LC3 lipidation confirmed in human muscle biopsiesObservational; mechanism confirmed in humans—
TrehaloseProposed to induce autophagy via TFEB; preclinical onlyRodent neurodegeneration models— unsourced — trehalose-TFEB mechanism pending citation

Autophagy as an epistasis target for multiple longevity interventions — the strongest mechanistic claim is that autophagy is a required downstream effector for several different longevity pathways; abolishing it genetically blocks the longevity benefit of CR, rapamycin, and IIS reduction in invertebrates. Whether this epistasis holds in mammals is under investigation. needs-human-replication

Targeted interventions

TABLE WITHOUT ID file.link AS Compound, mechanisms AS Mechanism, clinical-stage AS Stage, human-evidence-level AS "Evidence", translation-gap AS "Gap"
FROM "molecules/compounds" OR "interventions"
WHERE contains(hallmarks, [[disabled-macroautophagy]])
  OR contains(target-hallmarks, [[disabled-macroautophagy]])
SORT clinical-stage DESC

See interventions-by-hallmark for the full matrix, class-level synthesis, and gaps. Autophagy epistasis makes this hallmark a convergence point for multiple longevity interventions.

Cross-references

Process pages

Protein pages — machinery

  • ulk1 (verified) · atg13 (verified) · atg101 (verified) — initiation complex
  • beclin-1 (verified) — nucleation scaffold; BCL-2/autophagy switch
  • atg5 (verified) · atg7 (verified) · atg12 (verified) — elongation conjugation
  • lc3 (verified) — autophagosome membrane marker
  • tfeb (verified) — master transcriptional regulator
  • p62 (verified) — cargo receptor + flux reporter

Protein pages — mitophagy receptors

  • pink1 (verified) · parkin (verified) · pink1-parkin-pathway (verified) — ubiquitin-driven mitophagy
  • ndp52 (verified) · optn (verified) — secondary mitophagy receptors
  • bnip3 (verified) · nix (verified) — receptor-mediated mitophagy
  • fundc1 (verified) — hypoxia-induced mitophagy
  • bcl2l13 (verified) — AMPKα2-dependent cardioprotective mitophagy

Pathway and regulatory pages

  • mtor (verified) — primary autophagy suppressor
  • ampk (verified) — primary autophagy activator
  • pink1-parkin-pathway (verified) — mitophagy signaling cascade

Intervention pages

Hypothesis pages

  • hyperfunction-theory (verified) — mTORC1 hyperfunction is the proximal upstream driver of autophagy suppression in aging

Position in causal hierarchy

This hallmark is classified as Intermediate response/damage tier (mechanistic-tier: intermediate / intervention-tractability: high). See hallmark-causality-graph for the full hierarchy and intervention-sequencing argument.

Direct upstream nodes per caused-by: frontmatter: deregulated-nutrient-sensing (mTORC1 → ULK1 inhibition; AMPK decline releases mTOR brakes). Direct downstream nodes per causes: frontmatter: loss-of-proteostasis (Atg5/Atg7 KO → ubiquitin inclusions + neurodegeneration), mitochondrial-dysfunction (impaired mitophagy → damaged organelle accumulation), chronic-inflammation (impaired DAMP clearance → NF-κB activation). Edge evidence is in causal-graph-data.

Limitations and gaps

  • Most mechanistic evidence is preclinical. Genetic lifespan-extension experiments (Atg5 Tg, Beclin-1 F121A) are mouse-only. Whether restoring autophagy in humans extends healthspan or lifespan is not yet testable directly. needs-human-replication
  • Tissue-specific heterogeneity. Neurons and cardiomyocytes are the most autophagy-dependent post-mitotic cells. Some proliferating cell types may tolerate or benefit from lower autophagy. Cell-type generalizations should be used cautiously.
  • Autophagy flux measurement in humans is difficult. Most human aging data comes from peripheral blood cells or post-mortem tissue; in-vivo flux in the most-affected organs (brain, heart) is technically inaccessible. needs-human-replication
  • The optimal autophagy dose is unknown. Evidence from cancer biology suggests excessive autophagy can be harmful; whether a hormetic U-shaped dose-response exists in aging tissues is unsettled. dose-response-unclear
  • Senescence-autophagy link is incompletely sourced on this wiki. The claim that autophagy deficiency stabilizes the senescent phenotype needs dedicated primary citations on the atomic pages. unsourced
  • Trehalose autophagy mechanism needs a primary citation. The TFEB-mediated mechanism for trehalose-induced autophagy is widely stated but the primary citation is absent on this wiki. unsourced
  • TFEB decline with age in humans. Direct evidence for TFEB nuclear localization decline in human aged tissues is thin; most data from mouse liver and C. elegans. needs-human-replication

Footnotes

Footnotes

  1. doi:10.1038/nature04724 · in-vivo · model: Nestin-Cre Atg5 conditional KO mice · progressive motor deficit + ubiquitin inclusions + neurodegeneration; cited on atg5 (verified) ↩

  2. doi:10.1038/nature04723 · in-vivo · model: Nestin-Cre Atg7 conditional KO mice · same neurodegeneration phenotype as Hara 2006, confirming non-redundancy; n=26 mutant / 41 control; all mutants dead within 28 weeks (P<0.01); cited on atg7 (verified) ↩

  3. doi:10.1038/45257 · in-vivo · model: Becn1+/− mice · increased tumorigenesis; cited on beclin-1 (verified — this specific claim is not_oa per beclin-1 verified scope; qualitative claim retained) ↩

  4. doi:10.1038/ncomms3300 · in-vivo · model: C57BL/6 pCAGGS-Atg5 ubiquitous transgenic mice · n=65 WT + 70 Tg · log-rank χ²=17.32 p<0.001 · ~17.2% median lifespan extension; cited on atg5 (verified) ↩

  5. doi:10.1038/s41586-018-0162-7 · in-vivo · model: Beclin-1 F121A knock-in mice (pure C57BL/6J, >12 backcross generations) · n=68 WT + 102 KI (combined); p<0.0001 log-rank · WT median 26 mo vs KI median 29 mo (~12% extension, both sexes); cited on beclin-1 (verified) ↩

  6. doi:10.1038/s41580-018-0033-y · review · multi-organism · autophagy epistasis evidence aggregated; cited on autophagy (verified) ↩

Graph View

Backlinks